Table 1.
Patient characteristics
| Patients | Total cohort | UWCCC | OIL | p* |
|---|---|---|---|---|
| N = 58 (%) | N = 29 (%) | N = 29 (%) | ||
| Age; mean (±sd) (yr) | 61 (14) | 57 (15) | 65 (13) | 0.02 |
| Gender | 1 | |||
| Male | 32 (55%) | 16 (55%) | 16 (55%) | |
| Actionable mutation | 0.4 | |||
| BRAF wild type | 38 (66%) | 18 (62%) | 20 (69%) | |
| BRAF mutated | 10 (17%) | 5 (17%) | 5 (17%) | |
| Mutations other than BRAF | 7 (12%) | 6 (21%) | 1 (4%) | |
| Unknown | 3 (5%) | 0 (0%) | 3 (10%) | |
| ECOG performance status | 0.001 | |||
| 0 | 30 (51%) | 17 (59%) | 13 (45%) | |
| 1 | 15 (26%) | 3 (10%) | 12 (41%) | |
| 2 | 4 (7%) | 0 (0%) | 4 (14%) | |
| Unknown | 9 (16%) | 9 (31%) | 0 (0%) | |
| Anatomic site of primary | 0.6 | |||
| Cutaneous | 48 (83%) | 21 (73%) | 27 (94%) | |
| Mucosal | 4 (7%) | 3 (10%) | 1 (3%) | |
| Ocular | 2 (3%) | 2 (7%) | 0 (0%) | |
| Unknown primary | 4 (7%) | 3 (10%) | 1 (3%) | |
| Treatment setting | 0.001 | |||
| Adjuvant setting | 10 (17%) | 10 (34%) | 0 (0%) | |
| Metastatic setting | 48 (83%) | 19 (66%) | 29 (100%) | |
| Best response — only for metastatic disease (N=48) | 0.8 | |||
| Complete response | 17 (35%) | 8 (42%) | 9 (31%) | |
| Progressive disease | 10 (21%) | 5 (26%) | 5 (17%) | |
| Radiographic response | 14 (29%) | 3 (16%) | 11 (38%) | |
| Mixed radiographic response | 6 (13%) | 2 (11%) | 4 (14%) | |
| Other | 1 (2%) | 1 (5%) | 0 (0%) | |
| Number of 18F-FDG PET/CT per patient, median (range) | 4 (2–16) | 3 (2–16) | 4 (2–11) | 0.5 |
Sd standard deviation, UWCCC University of Wisconsin Carbone Cancer Centre, OIL Institute of Oncology Ljubljana Slovenia,. *p value was calculated using Fisher’s exact test to compare the statistical difference in patients characteristics between UWCCC and OIL